MERIDIAN BIOSCIENCE: ADVANCING GLOBAL HEALTH THROUGH INNOVATIVE DIAGNOSTICS

Meridian Bioscience: Advancing Global Health Through Innovative Diagnostics

Meridian Bioscience: Advancing Global Health Through Innovative Diagnostics

Blog Article

Meridian Bioscience, Inc., headquartered in Cincinnati, Ohio, is a leading life science company specializing in the development, manufacturing, and distribution of diagnostic testing solutions and life science raw materials. Since its founding in 1976, Meridian has expanded its global reach, serving hospitals, laboratories, research centers, and biotech firms in over 70 countries.​






Core Business Divisions


Meridian operates through two primary divisions: Diagnostics and Life Science.​



Diagnostics Division


This division offers a comprehensive range of diagnostic platforms and tests, including:​





  • Revogene® Molecular Testing Platform: A fully automated system capable of single and multiplex testing with minimal hands-on time.​




  • Alethia® Molecular Testing Platform: An affordable LAMP-based system delivering qualitative results in under an hour.​




  • BreathID® Urea Breath Testing Platforms: Non-invasive tests for detecting Helicobacter pylori infections, suitable for various patient volumes.​




  • LeadCare® Blood Chemistry Testing Platform: A point-of-care system for diagnosing lead poisoning in clinical settings.​Meridian Bioscience




Life Science Division


Meridian supplies over 3,000 antigens and antibodies covering more than 500 diseases. Additionally, it offers a comprehensive range of specialty qPCR/RT-qPCR master mixes and molecular enzymes, all manufactured under ISO13485 regulations.​






COVID-19 Response and Innovations


In response to the COVID-19 pandemic, Meridian developed the Revogene® SARS-CoV-2 molecular assay, a real-time Reverse Transcription Polymerase Chain Reaction (rRT-PCR) test for detecting SARS-CoV-2 nucleic acid from various swab specimens.​






Strategic Acquisitions and Growth


In February 2020, Meridian acquired Exalenz Bioscience Ltd., an Israeli company specializing in urea breath test systems for detecting Helicobacter pylori infections. This acquisition added Exalenz’s flagship BreathID® Breath Test Systems to Meridian’s portfolio, enhancing its gastrointestinal diagnostic solutions.​


In January 2023, Meridian was acquired by SD Biosensor and SJL Partners in a $1.53 billion all-cash transaction. Under the terms of the merger, Meridian shareholders received $34.00 per share in cash, and the company ceased trading on the NASDAQ Global Select Market. Meridian continues to operate as an independent entity under new ownership, headquartered in Cincinnati, Ohio.​






Commitment to Public Health and Education


Beyond product development, Meridian is committed to public health education. Through Magellan Diagnostics, the company launched a national education initiative focusing on the risks of lead exposure for pregnant women. This program includes webinars, local educational events, and mobile blood lead testing to raise awareness and promote preventive measures.

Report this page